Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2982189 | 0.82 | ALDH1A1 (0.37) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| SCHEMBL2982187 | 0.82 | ALDH1A1 (0.37) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| SCHEMBL15304762 | 0.81 | MEN1 (0.37) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2983167 | 0.80 | ALDH1A1 (0.36) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL2983171 | 0.80 | ALDH1A1 (0.36) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| SCHEMBL13036948 | 0.80 | ALDH1A1 (0.36) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| SCHEMBL10538154 | 0.78 | TAS1R3 (0.37) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| SCHEMBL8232821 | 0.78 | KDM4E (0.38) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| SCHEMBL713948 | 0.78 | KDM4E (0.38) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 | |
| SCHEMBL713068 | 0.78 | KDM4E (0.38) | TAS1R3TAS1R1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LTD (AU) | 2015-11-05 | — | — | US | disclosed |
| US-9102708-B2 | Methods for the synthesis of dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2015-08-11 | — | — | US | disclosed |
| US-8759480-B2 | Contoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2014-06-24 | — | — | US | disclosed |
| US-8664256-B2 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2014-03-04 | — | — | US | disclosed |
| EP-1984386-B1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LTD (AU) | 2013-10-09 | — | — | EP | disclosed |
| US-20130123463-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-05-16 | — | — | US | disclosed |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | SYNGENE LIMITED (AU) | 2013-01-24 | — | — | US | disclosed |
| US-20130012560-A1 | KINESIN INHIBITORS AS CANCER THERAPEUTICS | ABRAMS TINYA (US) | 2013-01-10 | — | — | US | disclosed |
| US-8252832-B2 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20120142892-A1 | CONTOXIN ANALOGUES AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE-CONTAINING PEPTIDES | POLYCHIP PHARMACEUTICALS PTY LTD. (AU) | 2012-06-07 | — | — | US | disclosed |
| US-20090247744-A1 | HYDROFORMYLATION PROCESS FOR PHARMACEUTICAL INTERMEDIATE | DAUGS EDWARD D | 2009-10-01 | — | — | US | disclosed |
| US-20090239922-A1 | Kinesin inhibitors as cancer therapeutics | NOVARTIS AG (CH) | 2009-09-24 | — | — | US | disclosed |
| WO-2009077448-A1 | KINESIN INHIBITORS AS CANCER THERAPEUTICS | NOVARTIS AG (CH) | 2009-06-25 | — | — | WO | disclosed |
| US-7538190-B2 | Methods for the synthesis of two or more dicarba bridges in organic compounds | POLYCHIP PHARMACEUTICALS PTY LTD (AU) | 2009-05-26 | — | — | US | disclosed |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG | 2008-08-21 | — | — | US | disclosed |
| WO-2008063912-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | NOVARTIS AG (CH) | 2008-05-29 | — | — | WO | disclosed |
| US-20080027218-A1 | Hydroformylation Process for Pharmaceutical Intermediate | DAUGS EDWARD D | 2008-01-31 | — | — | US | disclosed |
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | SYNGENE LIMITED (AU) | 2007-08-23 | — | — | US | disclosed |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247744-A1 | HYDROFORMYLATION PROCESS FOR PHARMACEUTICAL INTERMEDIATE | ACE, ACE2, AGT | TAS1R3 4850/4885TAS1R1 4825/4885MEN1 2819/4885 |
| US-20080027218-A1 | Hydroformylation Process for Pharmaceutical Intermediate | ACE, ACE2, AGT | TAS1R3 4855/4885TAS1R1 4830/4885MEN1 2831/4885 |
| US-20130023645-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, CDCA2 | TAS1R3 4135/4885TAS1R1 4505/4885MEN1 73/4885 |
| US-20130123463-A1 | METHODS FOR THE SYNTHESIS OF TWO OR MORE DICARBA BRIDGES IN ORGANIC COMPOUNDS | OTC, NBAS, IDH2 | TAS1R3 4529/4885TAS1R1 4742/4885MEN1 1229/4885 |
| US-20070037853-A1 | N-(3-aminopropyl)-N-{1-[1-benzyl-4-(3-chlorophenyl)-1H-imidazol-2-yl]-2-methylpropyl}morpholine-4-carboxamide and derivatives; kinesin spindle protein (KSP) inhibitors; anticarcinogenic agents; antimiotic; gene expression inhibition | KIF5B, KIF2C, KIF18B | TAS1R3 4428/4885TAS1R1 4529/4885MEN1 4230/4885 |
| US-20120142892-A1 | CONTOXIN ANALOGUES AND METHODS FOR SYNTHESIS OF INTRAMOLECULAR DICARBA BRIDGE-CONTAINING PEPTIDES | VIP, CANX, INHA | TAS1R3 3348/4885TAS1R1 3740/4885MEN1 1446/4885 |
| US-20080200462-A1 | SUBSTITUTED PYRAZOLE AND TRIAZOLE COMPOUNDS AS KSP INHIBITORS | CYP3A43, ABCG2, CYP3A7 | TAS1R3 1303/4885TAS1R1 1866/4885MEN1 3643/4885 |
| US-20090239922-A1 | Kinesin inhibitors as cancer therapeutics | KIF5B, KIF18B, KIF18A | TAS1R3 3863/4885TAS1R1 3996/4885MEN1 3980/4885 |
| US-20130012560-A1 | KINESIN INHIBITORS AS CANCER THERAPEUTICS | KIF5B, KIF18B, KIF18A | TAS1R3 3863/4885TAS1R1 3996/4885MEN1 3980/4885 |
| US-20150315243-A1 | METHODS FOR THE SYNTHESIS OF DICARBA BRIDGES IN ORGANIC COMPOUNDS | DCLRE1A, RNF168, MTCL3 | TAS1R3 4221/4885TAS1R1 4547/4885MEN1 67/4885 |
| US-20070197771-A1 | Methods for the synthesis of two or more dicarba bridges in organic compounds | OTC, NBAS, IDH2 | TAS1R3 4529/4885TAS1R1 4742/4885MEN1 1229/4885 |
| US-20070197429-A1 | Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides | VIP, NRDC, INHA | TAS1R3 2684/4885TAS1R1 3087/4885MEN1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.